Work

Supplemental Figure S1 and Figure S2 from ADAM17 is a Tumor Promoter and Therapeutic Target in Western Diet–associated Colon Cancer

Year: 2023

Type: supplementary-materials

Abstract: Fig S1. BMS566394 inhibits EGFR signaling in CXCL12 treated HCT116 cells; Fig S2. Schema for CXCL12-CXCR4 transactivation of colon cancer cell EGFR. Shown in the figure are inhibitors or antibodies used in this study: AMD3100 blocks CXCR4; BMS566394 blocks ADAM17 and INCB3619 blocks ADAM17 and ADAM10; C225 antibodies block ligand binding to EGFR.

DOI: 10.1158/1078-0432.22468697

Authors: Reba Mustafi, Urszula Dougherty, Devkumar Mustafi, Fatma Ayaloglu-Butun, Michelle Fletcher, Sarbani Adhikari, Farhana Sadiq, Katherine Meckel, Haider I. Haider, Abdurahman Khalil, Joel Pekow, Vani Konda, Loren Joseph, John Hart, Alessandro Fichera, Yan Chun Li, Marc Bissonnette

Language: English

Topic: Protease and Inhibitor Mechanisms

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361886877

Cites:

Cited by:

Related to: 10